Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL
Status:
Not yet recruiting
Trial end date:
2039-03-01
Target enrollment:
Participant gender:
Summary
Phase I Dose Finding: To identify the MTD of CAR19-tTregs defined as the dose level that most
closely corresponds to a dose limiting toxicity rate (DLT) of <25%.
Phase II Extension: To determine preliminary efficacy estimate as measured by overall
response rate (ORR, complete response [CR] + partial response [PR]) at MTD of CAR19tTreg by
day +28.